Skip to main content
. 2023 Mar 15;5(4):123–132. doi: 10.1253/circrep.CR-22-0120

Table 2.

Baseline Characteristics, Including Cardiocerebrovascular Thromboembolism Risks Overall and in TLF and Non-TLF Groups Separately

  Total
(n=872)
TLF
(n=62)
Non-TLF
(n=810)
P value
Cardiocerebrovascular thromboembolism risk
 CHADS2 score 2.25±1.00 2.52±0.90 2.23±1.01 0.015
  CHADS2 score ≥2 (%) 77.6 90.3 76.7 0.013
  CHADS2 score ≥3 (%) 37.7 50.0 36.8 0.039
  CHADS2 score ≥4 (%) 9.6 11.3 9.5 0.646
 CHA2DS2-VASc score 4.87±1.66 5.11±1.52 4.85±1.67 0.188
  CHA2DS2-VASc score ≥4 (%) 78.9 82.3 78.6 0.501
  CHA2DS2-VASc score ≥5 (%) 57.1 71.0 56.0 0.022
  CHA2DS2-VASc score ≥6 (%) 34.9 37.1 34.7 0.702
 CHA2DS2-VASc-HS score 6.29±1.71 6.69±1.57 6.26±1.71 0.039
  CHA2DS2-VASc-HS score ≥6 (%) 66.7 75.8 66.0 0.116
  CHA2DS2-VASc-HS score ≥7 (%) 44.5 58.1 43.5 0.026
  CHA2DS2-VASc-HS score ≥8 (%) 24.8 24.2 24.8 0.913
 Score componentsA
  C (%) 21.4 43.5 19.8 <0.001
  H (%) 91.1 91.9 91.0 0.801
  Age (year) 71.2±10.0 70.6±9.8 71.2±10.0 0.643
  A2 (%) 44.6 43.5 44.7 0.861
  D (%) 58.7 69.4 53.3 0.015
  S2 (%) 4.4 1.6 4.6 0.272
  V (%) 63.5 67.7 63.2 0.475
  A (%) 31.0 32.3 30.9 0.819
  Sc (%) 78.4 72.6 78.9 0.244
  H (%) 98.5 98.4 98.5 0.934
  S (%) 49.7 59.7 43.0 0.011
Other patient characteristics
 eGFR (mL/min/1.73 m2) 54.7±23.1 46.1±26.4 55.3±22.7 0.002
 CKD (%)
  Stage 5D (hemodialysis) 8.7 21.0 7.8 <0.001
  Stage 3b to 5 exp 5D 19.5 21.0 19.5 0.780
 Serum hemoglobin (g/dL) 12.7±2.0 11.9±1.91 12.8±1.99 <0.001
 Anemia (%) 47.0 69.4 45.3 <0.001
 BMI (kg/m2) 24.0±3.9 22.8±4.18 24.1±3.85 0.015
 Low (≤18.4 kg/m2) BMI (%) 5.3 14.5 4.6 <0.001
Lesion characteristics (%)
 Left anterior descending artery 42.8 37.1 43.2 0.348
 Left circumflex artery 19.8 17.7 20.0 0.667
 Right coronary artery 33.7 38.7 33.3 0.388
 Left main coronary artery 3.4 6.5 3.2 0.177
 Diffuse 46.3 61.3 45.1 0.014
 Proximal tortuosity 6.4 8.1 6.3 0.584
 Bending 18.2 29.0 17.4 0.022
 Calcification 28.3 50.0 26.7 <0.001
 Chronic total occlusion 5.8 11.3 5.4 0.058
 Ostium 15.6 19.4 15.3 0.397
 Bifurcation 28.7 27.4 28.8 0.821
Procedural characteristics
 No. DES 1.33±0.58 1.47±0.67 1.32±0.57 0.082
 Balloon size (mm) 3.58±0.63 3.44±0.59 3.59±0.63 0.049
 Total DES length (mm) 37.8±23.7 44.0±25.7 37.3±23.4 0.047
 Total DES length ≥60 mm (%) 18.6 27.4 17.9 0.063
 Pressure (atm) 16.1±3.3 15.5±3.1 16.1±3.3 0.154
 Debulking device use (%) 10.2 22.6 9.3 <0.001
Quantitative coronary angiography
 Preprocedural MLD (mm) 1.05±0.557 0.876±0.475 1.06±0.561 0.004
 Preprocedural %DS 56.5±21.0 59.7±20.9 56.2±21.0 0.211
 Post-procedural MLD (mm) 2.67±0.54 2.49±0.47 2.68±0.55 0.003
 Post-procedural %DS 11.9±6.9 15.4±8.9 11.7±6.6 0.001
 Post-procedural %DS ≥20 (%) 11.1 22.6 10.2 0.003
 Post-procedural RD (mm) 3.04±0.59 2.96±0.54 3.04±0.60 0.272
Clinical outcomes
 Clinical observational interval (days) 411±438 382±299 414±447 0.436
 All-cause death (%) 4.7 32.3 2.6 <0.001
 TLF (%) 7.1 100 0 1.000
 Cardiac death (%) 2.2 30.6 0 <0.001
 Non-fatal MI (%) 0.2 3.2 0 <0.001
 Angiographic TVR (%) 4.4 66.1 0 <0.001
 Clinical TLR (%) 1.8 25.8 0 <0.001
 Angiographic TLR (%) 3.9 54.8 0 <0.001

Unless specified otherwise, data are given as the mean±SD or as percentages. AFor definitions of individual score components, see Table 1. BMI, body mass index; CKD, chronic kidney disease; DES, drug-eluting stent; %DS, percentage diameter stenosis; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; MLD, minimum lumen diameter; RD, reference vessel diameter; TLF, target lesion failure; TLR, target lesion revascularization; TVR, target vessel revascularization.